In a major endorsement of their Chinese partner’s drug development prowess, France’s Transgene is swapping ownership of a joint venture — and control of their assets — for a stake in Tasly Biopharma, the biopharma arm of the Chinese medicine giant.
In a major endorsement of their Chinese partner’s drug development prowess, France’s Transgene is swapping ownership of a joint venture — and control of their assets — for a stake in Tasly Biopharma, the biopharma arm of the Chinese medicine giant.